Thursday, July 26, 2012 7:40:32 PM
What disturbs me is that he has to refer to the emails he is getting regarding an "expected" Prurisol PR and that he has to remind people that they are being as "transparent" and upfront as possible.
This indicates to me that there are some "not so nice" people who are abusing the generosity of Mr.Ehrlich and possibly causing him to even get a little "defensive".
I personally am disgusted by this and although it is out of my control,I will watch to find out who may be responsible for this behavior.If I find out who,I will plaster it over ihe internet.I believe I also have a number of "associates" who will assist me in this.
I will also make sure that I will not share anymore info on this board.I will only share with those I know , trust,and have some "class".Leo has been our "BEST FRIEND".DON'T F..K it up.As Dr.Banner (The Hulk)says "You won't like me when I'm angry".DON'T DESTROY OPEN COMMUNICATIONS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!![/u](and don't p.ss me off)Kelt (See Below)
Hi Jim,
It’s true we are very busy now, but I felt it important to get back to you and answer your question.
Post 3614 by DrFeelgood is a very good estimation of the phase 1 study. Regarding Post 3618, it’s not that the patient has 3 months to live, but has at least 3 months to live.
Some additional points. I hope they’ll help you better understand our phase 1 trial.
Cellceutix will be starting a Phase 1 trial in which Kevetrin will be given as an intravenous infusion to cancer patients. Kevetrin will be given in increasing doses to determine the maximum dose that can be given based on safety endpoints, according to standard NCI and NIH guidelines. Kevetrin will be given as a 1 hour infusion to a cohort of 3 patients once weekly for 3 weeks with a 1 week rest period (1 cycle). The dose will be increased for each cohort of patients, as long as the side effects are acceptable. Patients are expected to receive at least 2 cycles of drug; however, if patients respond they may continue treatment indefinitely. Once the highest dose is reached that is well-tolerated, a Phase 2 trial can then begin.
Regarding Prurisol, the other topic in my email, I have been getting emails that people are expecting a press release. ????????????
I had previously written you…
“It is important that when considering a strategy for Prurisol take into account that management interests are aligned with stockholders. Dr Menon and I are large stockholders of CTIX. At this time when the stock is trading at this level a major dilution is not a serious consideration. We need a little more time and will release our plan which we believe will be in the best interests of our shareholders and possibly generate significant value to CTIX.”
As you know when we had the IND declined by the FDA because of Formatech, we moved aggressively on remanufacturing the product, and preparing the documentation for a 505(b)2 on Prurisol. In addition we starting working with the hospital IRB and SRC. I believe this is very unusual that we accomplished getting the hospital approval and FDA approval on the same day.
You have to trust that we are not asleep at the wheel and we are working hard on our plan to get Prurisol into a human study ASAP.
When we finalize that plan, only then will we will issue a press release. And I reiterate … “will release our plan which we believe will be in the best interests of our shareholders and possibly generate significant value to CTIX.”
Leo Ehrlich
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM
Future Hospitality Ventures Unveils Bold, New AI-Driven Initiative to Revolutionize the $300 Billion Hospitality Market • NGTF • Oct 16, 2024 7:07 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • BURU • Oct 15, 2024 8:21 AM